A recently published study explores the possible benefits to discontinuing an alpha-1 blocker after receiving combination therapy with a 5-alpha reductase inhibitor for the treatment of benign prostatic hyperplasia (BPH). In more symptomatic patients, or patients with confirmed, enlarged prostates, it is recommended to use both medication classes (alpha-1 blocker and 5-alpha reductase inhibitor) to minimize symptoms by relaxing the prostatic smooth muscle and reducing the size of the prostate – producing a potentially synergistic effect. This study found that withdrawal of alpha 1-blockers after a year of combination therapy did not worsen urinary symptoms, QOL, and voiding or storage function. This provides evidence that combination therapy may not be needed indefinitely for all patients.
Guest Authors: Erica Crannage, PharmD and Stephanie Crist, PharmD
Music by Good Talk
Managing Pain in Patients with High Blood Pressure: Is There No Safe PATH?
Continuous Glucose Monitors (CGMs) - Patient Management Strategies and Getting Paid!
A Healthier Way to Commute? Cycling Reduces Mortality in Patients with Diabetes
Annual Wellness Visits: Pharmacists Closing Care Gaps
FOMO — Keeping Up With the Primary Literature
Could a DOAC Replace Warfarin to Treat the Thrombotic Antiphospholipid Syndrome?
The Top Ten Things Every Clinician Should Know About Sacubitril/Valsartan
Don’t Miss a Beat: The Importance of Influenza Vaccination in Patients with Coronary Disease
Why is Thor’s Hammer, Molnupiravir, Considered a 4th Line Option for COVID-19?
Top Ten Things Every Clinician Should Know about the 2022 Medical Standard of Care for Diabetes
On the Look Out for Prescribing Cascades
Thiazides in Chronic Kidney Disease: New Evidence Challenging Old Dogma
Sequential Additions or Multicomponent Combination? Should Our Approach to Hypertension Be Re-examined?
Extra Protection? Finerenone Use in Patients with Type 2 DM and CKD
Assessing HER Acceptability of Contraception
Preserving hope for patients with Heart Failure with Preserved Ejection Fraction (HFpEF)?
Top Ten Things Every Clinician Should Know about Continuous Glucose Monitors (CGM)
Spice Up Your Sleep Life with Saffron
Will a Dual GIP/GLP-1 Receptor Agonist SURPASS the Crowd?
Cut It Out! Removing EHR Allergy Warnings to Improve Antimicrobial Stewardship
Create your
podcast in
minutes
It is Free
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive